As a top vaccine maker, GlaxoSmithKline has been a laggard in the COVID-19 vaccine race, but has put on a late burst of speed with a start of phase 3 trials of a second candidate that will
Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer's disease candidate semorinemab hit one of its objectives in a phase 2 trial, although it missed another.
A drug for Wilson disease developed by AstraZeneca's Alexion rare disease unit has cleared a phase 3 trial, setting up regulatory filings in the coming months.
Just a month after getting approval for its new pneumococcal vaccine Vaxneuvance in adults, Merck & Co has reported positive trial results in children that will ramp up the pressure on
Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal with Lycia Therapeutics spanning up to five drug targets.
Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of months, agreeing a partnership with CRISPR specialist Arbor Biotechnologies that coul